Drug profile

The FDA adverse-event record for Zanthin,Proprietary Hyaluronic Acid, Akba Boswellia Serrata, Biovaflex, Vitamin D3

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Zanthin,Proprietary Hyaluronic Acid, Akba Boswellia Serrata, Biovaflex, Vitamin D3. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
5.9%
death-coded share
Dog
most-reported species
4
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
1
Deaths Reported
5.9%
Death Rate

Active Ingredients

Zanthin,Proprietary Hyaluronic Acid, Akba Boswellia Serrata, Biovaflex, Vitamin D3

Administration Routes

OralUnknown

Species Affected

Dog 17

Most Affected Breeds

Retriever - Labrador 3
Terrier - Rat 2
Crossbred Canine/dog 2
Bulldog 2
Poodle (unspecified) 1
Shepherd Dog - Australian 1
Beagle 1
Pug 1
Collie - Border 1
Terrier - Irish Soft-coated Wheaten 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Vomiting 4
Elevated creatinine 3
Not eating 3
Panting 3
Weight loss 2
Pain NOS 2
Diarrhoea 2
Allergy NOS 2
Seizure NOS 1
Elevated alanine aminotransferase (ALT) 1
Elevated serum alkaline phosphatase (SAP) 1

Outcome Breakdown

Recovered/Normal
6 (35.3%)
Ongoing
6 (35.3%)
Outcome Unknown
4 (23.5%)
Died
1 (5.9%)

Zanthin,Proprietary Hyaluronic Acid, Akba Boswellia Serrata, Biovaflex, Vitamin D3 Adverse Event Insights

17 reports name Zanthin,Proprietary Hyaluronic Acid, Akba Boswellia Serrata, Biovaflex, Vitamin D3; 1 recorded a death outcome (5.9% of reported events, not a population-level mortality rate). Active ingredient: Zanthin,Proprietary Hyaluronic Acid, Akba Boswellia Serrata, Biovaflex, Vitamin D3. Administration routes: Oral, Unknown.

By species: Dog (17 reports). By breed: Retriever - Labrador (3), Terrier - Rat (2), Crossbred Canine/dog (2).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (4), Vomiting (4), Elevated creatinine (3), Not eating (3). Outcome, 17 coded reports: Recovered/Normal leads at 35.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.